| HOME >> BIOLOGY >> TECHNOLOGY |
Dr. Chowrira earned his Ph.D. in Microbiology and Molecular Genetics from the University of Vermont and his J.D. degree from the College of Law at the University of Denver. He earned his M.S. in Molecular Virology from Illinois State University and his B.Sc. in Microbiology from the University of Agricultural Sciences, Bangalore, India.
"I am delighted to be joining a company that is the industry leader in PEGylation and polymer chemistry -- and has the approved products, partnerships and pipeline to prove it," said Dr. Chowrira. "Moreover, Nektar has the fundamentals, expertise, and validated platform technology necessary to rapidly build and expand its pipeline and partnerships, particularly through the development of high-value PEGylated small molecules and biologics."
About Nektar
Nektar Therapeutics is a biopharmaceutical company that develops and
enables differentiated therapeutics with its industry-leading PEGylation
and pulmonary drug development technology platforms. Nektar PEGylation and
pulmonary technology, expertise, manufacturing capabilities have enabled
eight approved products for partners, which include the world's leading
pharmaceutical and biotechnology companies. Nektar also develops its own
products by applying its PEGylation and pulmonary technology platforms to
existing medicines with the objective to enhance performance, such
'/>"/>
| SOURCE Nektar Therapeutics Copyright©2008 PR Newswire. All rights reserved |